Neurimmune Holdings AG

Biogen, Inc. ’s decision to discontinue commercialization and terminate its ongoing research with Alzheimer’s treatment Aduhelm does not appear to release the sponsor from data transparency requiremen

Biogen, Inc. 's decade-long Aduhelm (aducanumab) story line took many twists and turns over the course of its development, capturing national attention in 2021 when the drug became the first anti-amyl

Biogen, Inc. 's decade-long Aduhelm (aducanumab) story line took many twists and turns over the course of its development, capturing national attention in 2021 when the drug became the first anti-amyl

Trends in Swiss biotech financing last year mostly reflected global biotech doldrums as a result of macroeconomic challenges, according to the Swiss Biotech Report 2023. Equity and debt markets were d